Alanagreh Lo'ai, Alzoughool Foad, Atoum Manar
Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, Hashemite University, Jordan.
Int J Risk Saf Med. 2020;31(3):111-116. doi: 10.3233/JRS-200024.
The emerging COVID-19 pandemic poses a threat to the global health care system. Given the lack of antiviral therapies or vaccines for the disease, the antimalarial drug hydroxychloroquine (HCQ) obtained much attention as a treatment for COVID-19. However, there are limited and uncertain clinical data to support the beneficial effect of this drug in COVID-19 treatment. HCQ has several side effects and warnings, including blindness, heart failure, and renal toxicity, even with recommended doses. For severe cases of COVID-19 or in patients with preexisting conditions, administering such a drug could be fatal, particularly when taken at high doses or in combination with other antibiotics. However, further well-designed studies that would address the optimal dose, duration of treatment, possible side effects, and long-term usage outcomes are needed to make the final decision. In this paper, we aim to discuss the risk of using HCQ in treating COVID-19 patients, including its possible side effects.
新出现的新冠疫情对全球医疗系统构成了威胁。鉴于该疾病缺乏抗病毒疗法或疫苗,抗疟药物羟氯喹(HCQ)作为新冠治疗药物备受关注。然而,支持该药物在新冠治疗中有益效果的临床数据有限且不确定。即使是推荐剂量,HCQ也有多种副作用和警示,包括失明、心力衰竭和肾毒性。对于新冠重症病例或有基础疾病的患者,使用这种药物可能是致命的,尤其是高剂量服用或与其他抗生素合用时。然而,需要进一步设计良好的研究来确定最佳剂量、治疗时长、可能的副作用及长期使用效果,才能做出最终决定。在本文中,我们旨在探讨使用HCQ治疗新冠患者的风险,包括其可能的副作用。